Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells

American Journal of Transplantation

Volumn 15, Issue 6, 2015, Pages 1475-1483

  McCarthy, D P ^a   Bryant, J ^a   Galvin, J P ^a   Miller, S D ^a   Luo, X ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Basic (laboratory) research science; cell death: apoptosis; dendritic cell; immunobiology; islet transplantation; T cell biology; tolerance; translational research science

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; AUTOANTIGEN; CYTOKINE;

ALLOIMMUNITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNITY; BONE MARROW CELL; CHRONIC GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION RISK; INNATE IMMUNITY; LEUKOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN DONOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE; ALLOTRANSPLANTATION; ANIMAL; ANIMAL MODEL; CELLULAR IMMUNITY; CYTOLOGY; DONOR; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; APOPTOSIS; CYTOKINES; ETHYLDIMETHYLAMINOPROPYL CARBODIIMIDE; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, INNATE; IMMUNOTHERAPY; LEUKOCYTES; MODELS, ANIMAL; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTS;

EID: 84929317186     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13237     Document Type: Review

References (88)

1. Grinyo JM., Why is organ transplantation clinically important ? Cold Spring Harb Perspect Med 2013; 3.
2. Marsh SG, Albert ED, Bodmer WF, et al., Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010; 75: 291-455.
3. Lindahl KF, Wilson DB., Histocompatibility antigen-activated cytotoxic T lymphocytes. I. Estimates of the absolute frequency of killer cells generated in vitro. J Exp Med 1977; 145: 500-507.
4. Lindahl KF, Wilson DB., Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med 1977; 145: 508-522.
5. Felix NJ, Allen PM., Specificity of T-cell alloreactivity. Nat Rev Immunol 2007; 7: 942-953.
6. Morris GP, Allen PM., Cutting edge: Highly alloreactive dual TCR T cells play a dominant role in graft-versus-host disease. J Immunol 2009; 182: 6639-6643.
7. Morris GP, Uy GL, Donermeyer D, Dipersio JF, Allen PM., Dual receptor T cells mediate pathologic alloreactivity in patients with acute graft-versus-host disease. Sci Transl Med 2013; 5: 188ra174.
8. Adams AB, Williams MA, Jones TR, et al., Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
9. Jenkins MK, Schwartz RH., Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302-319.
10. Vincenti F, Charpentier B, Vanrenterghem Y, et al., A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
11. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ., CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307-328.
12. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL., Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512-521.
13. Phillips NE, Greiner DL, Mordes JP, Rossini AA., Costimulatory blockade induces hyporesponsiveness in T cells that recognize alloantigen via indirect antigen presentation. Transplant 2006; 82: 1085-1092.
14. Kishimoto K, Yuan X, Auchincloss H Jr., Sharpe AH, Mandelbrot DA, Sayegh MH., Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol 2004; 15: 2423-2428.
15. Zheng XX, Markees TG, Hancock WW, et al., CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162: 4983-4990.
16. Henn V, Slupsky JR, Grafe M, et al., CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
17. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB., Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. NatMed 2000; 6: 114.
18. Chen Y, Heeger PS, Valujskikh A., In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol 2004; 172: 5456-5466.
19. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, et al., Cutting edge: CD28 controls peripheral homeostasis of CD4 + CD25+ regulatory T cells. J Immunol 2003; 171: 3348-3352.
20. Riella LV, Liu T, Yang J, et al., Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012; 12: 846-855.
21. Mansour H, Homs S, Desvaux D, et al., Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol 2008; 19: 2277-2281.
22. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S., Induced immune tolerance for kidney transplantation. New Eng J Med 2011; 365: 1359-1360.
23. Brunstein CG, Miller JS, Cao Q, et al., Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011; 117: 1061-1070.
24. Morelli AE, Thomson AW., Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610-621.
25. Miller SD, Wetzig RP, Claman HN., The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med 1979; 149: 758-773.
26. Sulzberger MB., Hypersensitivities to arsphenamine in guinea pigs: Experiments in prevention and in desensitization. Arch Derm Syph 1929; 20: 669-697.
27. Chase MW., Inhibition of experimental drug allergy by prior feeding of the sensitizing agent. Proc Soc Exp Biol Med 1946; 61: 257-259.
28. Battisto JR, Bloom BR., Dual immunological unresponsiveness induced by cell membrane coupled hapten or antigen. Nature 1966; 212: 156-157.
29. Ezzelarab MB, Zahorchak AF, Lu L, et al., Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant 2013; 13: 1989-2005.
30. Penna G, Adorini L., 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-2411.
31. Macedo C, Turnquist HR, Castillo-Rama M, et al., Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells. Am J Transplant 2013; 13: 2322-2333.
32. Smyth LA, Ratnasothy K, Moreau A, et al., Tolerogenic donor-derived dendritic cells risk sensitization in vivo owing to processing and presentation by recipient APCs. J Immunol 2013; 190: 4848-4860.
33. Panula P, Happola O, Airaksinen MS, Auvinen S, Virkamaki A., Carbodiimide as a tissue fixative in histamine immunohistochemistry and its application in developmental neurobiology. J Histochem Cytochem 1988; 36: 259-269.
34. Johnson HM, Brenner K, Hall HE., The use of a water-soluble carbodiimide as a coupling reagent in the passive hemagglutination test. J Immunol 1966; 97: 791-796.
35. Turley DM, Miller SD., Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 2212-2220.
36. Getts DR, McCarthy DP, Miller SD., Exploiting apoptosis for therapeutic tolerance induction. J Immunol 2013; 191: 5341-5346.
37. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD., Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182: 75-85.
38. Smith CE, Miller SD., Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun 2006; 27: 218-231.
39. Smith CE, Eagar TN, Strominger JL, Miller SD., Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2005; 102: 9595-9600.
40. Pedotti R, Mitchell D, Wedemeyer J, et al., An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide. NatImmunol 2001; 2: 216-222.
41. Bielekova B, Goodwin B, Richert N, et al., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. NatMed 2000; 6: 1167-1175.
42. Lutterotti A, Yusef S, Sputtek A, et al., Antigen-specific tolerance by autologous myelin peptide-coupled cells: A phase 1 trial in multiple sclerosis. Sci Transl Med 2013; 5: 188ra75.
43. Busker AE, Miller SD, Melvold RW., Induction of allograft tolerance to the H-Y antigen in adult C57BL/6 mice: Differential effects on delayed-type hypersensitivity and cytolytic T-lymphocyte activity. Cell Immunol 1990; 125: 225-234.
44. Elliott C, Wang K, Miller SD, Melvold R., Ethylcarbodiimide as an agent for induction of specific transplant tolerance. Transplant 1994; 58: 966-968.
45. Chen G, Kheradmand T, Bryant J, et al., Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions. Am J Transplant 2012.
46. Luo X, Pothoven KL, McCarthy D, et al., ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A 2008; 105: 14527-14532.
47. Wang S, Zhang X, Zhang L, et al., Preemptive tolerogenic delivery of donor antigens for permanent allogeneic islet graft protection. Cell Transplant 2014.
48. O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT., Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 2002; 51: 2481-2488.
49. Hanayama R, Tanaka M, Miyasaka K, et al., Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 2004; 304: 1147-1150.
50. Kaneko K, Morelli AE, Wang Z, Thomson AW., Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival. Clin Immunol 2003; 108: 190-198.
51. Getts DR, Turley DM, Smith CE, et al., Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011; 187: 2405-2417.
52. Kheradmand T, Wang S, Bryant J, et al., Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J Immunol 2012; 189: 804-812.
53. Mebius RE, Kraal G., Structure and function of the spleen. Nat Rev Immunol 2005; 5: 606-616.
54. Arredouani MS, Palecanda A, Koziel H, et al., MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. J Immunol 2005; 175: 6058-6064.
55. Sasaki T, Horiuchi S, Yamazaki M, Yui S., Stimulation of macrophage DNA synthesis by polyanionic substances through binding to the macrophage scavenger receptor. Biol Pharm Bull 1996; 19: 449-455.
56. Sakai M, Miyazaki A, Hakamata H, et al., The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation. J Biol Chem 1996; 271: 27346-27352.
57. Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S., Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci U S A 1996; 93: 12456-12460.
58. Wermeling F, Chen Y, Pikkarainen T, et al., Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. J Exp Med 2007; 204: 2259-2265.
59. McGaha TL, Chen Y, Ravishankar B, van Rooijen N, Karlsson MC., Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen. Blood 2011; 117: 5403-5412.
60. Miyake Y, Asano K, Kaise H, Uemura M, Nakayama M, Tanaka M., Critical role of macrophages in the marginal zone in the suppression of immune responses to apoptotic cell-associated antigens. J Clin Invest 2007; 117: 2268-2278.
61. Getts DR, Martin AJ, McCarthy DP, et al., Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012; 30: 1217-1224.
62. Backer R, Schwandt T, Greuter M, et al., Effective collaboration between marginal metallophilic macrophages and CD8+ dendritic cells in the generation of cytotoxic T cells. Proc Natl Acad Sci U S A 2010; 107: 216-221.
63. Ravishankar B, Shinde R, Liu H, et al., Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance. Proc Natl Acad Sci U S A 2014; 111: 4215-4220.
64. Ibrahim MA, Coode WK, Takei F, Ellis JS, Chain BM, Katz DR,. Chemically modified antigen-presenting cells induce T lymphocyte allospecific hyporesponsiveness. J Immunol 1991; 147: 4086-4093.
65. Eagar TN, Karandikar NJ, Bluestone J, Miller SD., The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol 2002; 32: 972-981.
66. Francisco LM, Sage PT, Sharpe AH., The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-242.
67. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ., Programmed death-1 ligand 1 interacts specifically with the B 7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
68. Tanaka K, Albin MJ, Yuan X, et al., PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007; 179: 5204-5210.
69. Fife BT, Guleria I, Gubbels Bupp M, et al., Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006; 203: 2737-2747.
70. Shouval DS, Biswas A, Goettel JA, et al., Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 2014; 40: 706-719.
71. Sun J, Madan R, Karp CL, Braciale TJ., Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15: 277-284.
72. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM., IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224-1234.
73. Rodriguez-Garcia M, Porichis F, de Jong OG, et al., Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 2011; 89: 507-515.
74. Wells AD, Li XC, Li Y, et al., Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303-1307.
75. Yanagawa Y, Iwabuchi K, Onoe K., Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell functions. Immunology 2009; 127: 345-353.
76. Brennan TV, Jaigirdar A, Hoang V, et al., Preferential priming of alloreactive T cells with indirect reactivity. Am J Transplant 2009; 9: 709-718.
77. Albert MH, Yu XZ, Magg T., Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells. Clin Immunol 2008; 129: 381-393.
78. Corlett L, Davies DH., Reduced lysis by CD8+ cytotoxic T cells in mixed lymphocyte reactions induced via CD4+ T cells exposed to chemically modified antigen presenting cells. Immunology 1995; 84: 488-494.
79. Martin AJ, McCarthy D, Waltenbaugh C, Goings G, Luo X, Miller SD., Ethylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer Hya transplant protection by inhibiting CD154 upregulation. J Immunol 2010; 185: 3326-3336.
80. Sivaganesh S, Harper SJ, Conlon TM, et al., Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. J Immunol 2013; 190: 5829-5838.
81. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q., Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant 2014; 14: 27-38.
82. Roncarolo MG, Battaglia M., Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007; 7: 585-598.
83. Zhang N, Schroppel B, Lal G, et al., Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009; 30: 458-469.
84. Tsang JY, Tanriver Y, Jiang S, et al., Conferring indirect allospecificity on CD4 + CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118: 3619-3628.
85. Levine AG, Arvey A, Jin W, Rudensky AY., Continuous requirement for the TCR in regulatory T cell function. Nat Immunol 2014; 15: 1070-1078.
86. Gabrilovich DI, Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
87. Bryant J, Lerret NM, Wang JJ, et al., Preemptive donor apoptotic cell infusions induce IFN-gamma-producing myeloid-derived suppressor cells for cardiac allograft protection. J Immunol 2014; 192: 6092-6101.
88. Burns AM, Chong AS., Alloantibodies prevent the induction of transplantation tolerance by enhancing alloreactive T cell priming. J Immunol 2011; 186: 214-221.